Piper Jaffray analyst Edward Tenthoff is a buyer of Moderna ahead of the Phase I data on mRNA-1944 chikungunya virus antibody in the first half of 2019. While the analyst ascribes no value for mRNA-1944 itself, he believes these data will have important read-through to Moderna's emerging Orphan Disease pipeline. mRNA-1944 is Moderna's first systemic secreted mRNA therapeutic and will validate mRNA-3704 for methylmalonic acidemia, mRNA-3927 for propionic acidemi, mRNA-3283 for phenylketonuria, mRNA-3630 for Fabry's disease and several as yet undisclosed orphan disease programs, Tenthoff tells investors in a research note. The analyst keeps an Overweight rating on Moderna with a $24 price target.